Werewolf Therapeutics, Inc.HOWLNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank23
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P23
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-11.48%
Q2 20250.18%
Q1 2025-16.58%
Q4 202425.53%
Q3 2024-17.96%
Q2 202418.31%
Q1 202433.78%
Q4 2023-10.97%
Q3 202313.10%
Q2 2023-18.14%
Q1 2023-26.19%
Q4 202221.34%
Q3 2022-5.88%
Q2 202226.88%
Q1 2022-18.32%
Q4 202136.92%
Q3 202134.71%
Q2 202150.82%
Q1 2021-8.87%
Q4 20209.85%
Q3 202027.30%
Q2 202036.81%
Q1 20200.00%